Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Release Date: May 15, 2025

Expiration Date: May 15, 2026

Activity Overview

Melanoma represents the fifth most diagnosed cancer in the United States each year, with incidences continuing to rise. Over the past decade, targeted immunotherapies have been the mainstay of treatment for advanced melanoma cases. However, greater understanding of the unique tumor microenvironment in melanoma has led to new and emerging intratumoral agents (eg, genetically engineered oncolytic viruses). These agents have revolutionized the treatment landscape for this challenging malignancy.

This Community Practice Connections™ program provides an in-depth review of some highlights from the live program, “Melanoma Tumor Board: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies,” held in March 2025. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with advanced melanoma, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.

Target Audience

This educational activity is directed toward a primary target audience of interventional radiologists and a secondary target audience of medical oncologists, nurse practitioners, physician assistants, and nurses who treat patients with advanced melanoma.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Analyze clinical and safety evidence for second-line therapies, including oncolytic viruses, TILs, and combination immunotherapies, for patients with melanoma after progression on PD-1 inhibitors
• Identify imaging and procedural strategies for effective lesion prioritization during oncolytic immunotherapy
• Evaluate the current and evolving impact of oncolytic immunotherapy on interventional oncology practices in melanoma care
• Summarize the mechanisms, administration techniques, and clinical benefits of oncolytic viruses and combination therapies for melanoma

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource, LLC (PER^®) have no relevant financial relationships with ineligible companies.

PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.